These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26482622)

  • 1. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
    Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
    Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer.
    Chen MJ; Lin PL; Wang L; Cheng YM; Chen CY; Lee H
    Thorac Cancer; 2020 Jul; 11(7):1904-1910. PubMed ID: 32394538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness.
    Chen MJ; Wu DW; Wang YC; Chen CY; Lee H
    Sci Rep; 2016 Oct; 6():34933. PubMed ID: 27713506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
    Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
    Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
    Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation of P27 expression and localization to phosphorylated AKT in non-small cell lung cancer].
    Miao LJ; Wang J; Li SS; Wu YM; Wu YJ; Wang XC
    Ai Zheng; 2006 Oct; 25(10):1216-20. PubMed ID: 17059763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
    Wu DW; Wu TC; Wu JY; Cheng YW; Chen YC; Lee MC; Chen CY; Lee H
    Oncogene; 2014 Aug; 33(35):4385-95. PubMed ID: 24096476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of filamin-A protein is associated with aggressive phenotype and poor survival outcomes in NSCLC patients treated with platinum-based combination chemotherapy.
    Gachechiladze M; Skarda J; Janikova M; Mgebrishvili G; Kharaishvili G; Kolek V; Grygarkova I; Klein J; Poprachova A; Arabuli M; Kolar Z
    Neoplasma; 2016; 63(2):274-81. PubMed ID: 26774150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
    Hommura F; Dosaka-Akita H; Mishina T; Nishi M; Kojima T; Hiroumi H; Ogura S; Shimizu M; Katoh H; Kawakami Y
    Clin Cancer Res; 2000 Oct; 6(10):4073-81. PubMed ID: 11051259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
    Tian FM; Zhong CY; Wang XN; Meng Y
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
    Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
    Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
    Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
    Oshita F; Kameda Y; Nishio K; Tanaka G; Yamada K; Nomura I; Nakayama H; Noda K
    Oncol Rep; 2000; 7(3):491-5. PubMed ID: 10767357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of altered eIF3a and its association with p27 in non-small cell lung cancers.
    Shen J; Yin JY; Li XP; Liu ZQ; Wang Y; Chen J; Qu J; Xu XJ; McLeod HL; He YJ; Xia K; Jia YW; Zhou HH
    PLoS One; 2014; 9(4):e96008. PubMed ID: 24789280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
    Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
    Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    J Chemother; 2016 Jun; 28(3):225-9. PubMed ID: 25971309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.